TRIVAGIZOLE 3
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRIVAGIZOLE 3 (TRIVAGIZOLE 3).
Terconazole is an imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, disrupting ergosterol synthesis and fungal cell membrane integrity.
| Metabolism | Hepatic via cytochrome P450 enzymes, primarily CYP3A4 and CYP1A2. |
| Excretion | Renal excretion accounts for approximately 70-80% of the administered dose, with about 20% excreted as unchanged drug and the remainder as metabolites. Fecal excretion is minimal (<5%). |
| Half-life | Terminal elimination half-life is approximately 7-9 hours in healthy adults, allowing for twice-daily dosing. In patients with hepatic impairment, half-life may be prolonged up to 18 hours, requiring dose adjustment. |
| Protein binding | Approximately 90% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is 0.7-1.0 L/kg, indicating extensive tissue distribution, with high concentrations achieved in vaginal mucosa, skin, and nails. |
| Bioavailability | Vaginal cream: systemic absorption is minimal (<10%), with local bioavailability approaching 100% at the target site. Oral bioavailability is 40-60% when taken with food. |
| Onset of Action | For topical vaginal cream, onset of symptomatic relief (itching, discharge) typically occurs within 48-72 hours after initiation, with maximal effect by day 3. |
| Duration of Action | Duration of therapeutic effect is maintained for 24 hours with twice-daily application. Complete eradication of Candida species typically requires 3-7 days of continuous therapy. |
| Molecular Weight | 252.27 |
One vaginal tablet (200 mg) inserted intravaginally at bedtime for 3 consecutive days.
| Dosage form | CREAM |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for mild to moderate hepatic impairment; not studied in severe impairment. |
| Pediatric use | Safety and efficacy not established; not recommended for pediatric use. |
| Geriatric use | No specific dosage adjustment; use standard adult dosing with caution due to potential comorbidities and polypharmacy. |
| 1st trimester | Contraindicated: known teratogen (fetal hydantoin syndrome, neural tube defects). |
| 2nd trimester | Contraindicated: risk of hemorrhagic disease of newborn; use only if benefit outweighs risk. |
| 3rd trimester | Contraindicated: risk of neonatal hemorrhage, respiratory depression, and withdrawal syndrome. |
Clinical note
Comprehensive clinical and safety monograph for TRIVAGIZOLE 3 (TRIVAGIZOLE 3).
| Placental transfer | Significant; fetal serum levels approach maternal levels. |
| Breastfeeding | Excreted into breast milk; avoid breastfeeding due to risk of infant sedation, poor feeding, and withdrawal. Some sources suggest use with caution if maternal benefit outweighs risk. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to hydantoinsHistory of hepatotoxicity due to phenytoinSinus bradycardiaSinoatrial blockSecond- or third-degree AV blockAdams-Stokes syndromeConcurrent use with delavirdine
| Precautions | For intravaginal use only, not for ophthalmic or oral use., If irritation or sensitization occurs, discontinue use., May interact with latex products (e.g., condoms) causing reduced efficacy., Safety in pregnancy (Category C) not established; use only if clearly needed. |
| Food/Dietary | No significant food interactions. Avoid alcohol as it may worsen side effects such as dizziness or nausea. |
Loading safety data…
| L5 (Contraindicated) |
| Teratogenic Risk | FDA Pregnancy Category C. No adequate well-controlled studies in pregnant women. In animal studies, intravaginal administration of 200 mg/kg/day (11 times human dose) resulted in maternal toxicity and fetal effects including increased resorptions and reduced ossification. First trimester: limited data, avoid unless clearly needed. Second and third trimesters: systemic absorption is minimal (<2%) with vaginal use, but caution advised. Not associated with major malformations in available human data. |
| Fetal Monitoring | No specific monitoring required for standard use. For prolonged therapy or in high-risk pregnancies, monitor for vaginal irritation or hypersensitivity. If used in pregnancy, monitor for signs of preterm labor or infection persistence. |
| Fertility Effects | No known effect on fertility. Animal studies at doses up to 200 mg/kg/day showed no impairment of fertility. No human data on fertility alteration. |
| Clinical Pearls |
| Trivagizole 3 is a combination antifungal (clotrimazole 200 mg) for intravaginal use in vulvovaginal candidiasis. Three-day regimen improves compliance. If no response in 3 days, consider resistant species or alternative diagnosis. Avoid in pregnancy unless benefit outweighs risk; use 7-day regimen if pregnant. |
| Patient Advice | Insert one vaginal tablet at bedtime for 3 consecutive nights. · Complete full course even if symptoms improve. · Avoid sexual intercourse during treatment; may weaken latex condoms. · Do not use tampons, douches, or spermicides during therapy. · If symptoms persist after 3 days, consult healthcare provider. |